Sanofi Raises Annual Guidance On Upbeat Q2 Performance

Sanofi SA SNY posted a business net profit of €2.17 billion for Q2 FY22, +25.4% (+16.6% at CER). Sales reached €10.11 billion, +15.7% Y/Y (+8.1% at constant exchange rates (CER)). Business operating income rose 21.5% to €2.75 billion.
Best-selling eczema drug Dupixent, consumer healthcare, rare disease, and vaccines drove the growth.
Specialty Care grew 21.6%, driven by Dupixent +43.4% to €1.96 billion and double-digit growth in Rare Disease.
Vaccines were up 8.7% due to a strong rebound of Travel and Booster vaccines and continued growth in the Polio/Pertussis/Hib franchise.
Consumer healthcare delivered the 5th consecutive quarter of growth (+9.1% to €1.26 billion) driven by Cough & Cold, Allergy, and Digestive Wellness.
Guidance: Sanofi expects 2022 business EPS to grow approximately 15% at CER. The positive currency impact on 2022 business EPS is estimated between +7.5% to +8.5%.
Earlier, the company expected 2022 business EPS to grow low-double-digit at constant exchange rates, with a 4% - 5% positive currency impact.
Price Action: SNY shares traded 1.26% lower at $50.28 during pre-market trading on the last check Thursday.
Photo Via Company

Earnings Calendar